Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Equity: 2022-2025

Historic Return on Equity for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -0.29%.

  • Entrada Therapeutics' Return on Equity fell 42.00% to -0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.29%, marking a year-over-year decrease of 42.00%. This contributed to the annual value of 0.20% for FY2024, which is 22.00% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Return on Equity stood at -0.29%, which was down 56.15% from -0.18% recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Return on Equity peaked at 0.30% during Q2 2024, and registered a low of -0.42% during Q4 2022.
  • Over the past 3 years, Entrada Therapeutics' median Return on Equity value was -0.03% (recorded in 2023), while the average stood at -0.05%.
  • In the last 5 years, Entrada Therapeutics' Return on Equity skyrocketed by 68bps in 2024 and then tumbled by 48bps in 2025.
  • Over the past 4 years, Entrada Therapeutics' Return on Equity (Quarterly) stood at -0.42% in 2022, then skyrocketed by 40bps to -0.03% in 2023, then increased by 18bps to 0.15% in 2024, then crashed by 42bps to -0.29% in 2025.
  • Its Return on Equity was -0.29% in Q3 2025, compared to -0.18% in Q2 2025 and 0.06% in Q1 2025.